|
1
|
Bateman ME, Strong AL, McLachlan JA, Burow
ME and Bunnell BA: The effects of endocrine disruptors on
adipogenesis and osteogenesis in mesenchymal stem cells: A review.
Front Endocrinol (Lausanne). 7:1712016.
|
|
2
|
Noel SE, Mangano KM, Griffith JL, Wright
NC, Dawson-Hughes B and Tucker KL: Prevalence of osteoporosis and
low bone mass among Puerto Rican older adults. J Bone Miner Res.
33:396–403. 2018. View Article : Google Scholar :
|
|
3
|
Aldaghri NM, Aziz I, Yakout S, Aljohani
NJ, Al-Saleh Y, Amer OE, Sheshah E, Younis GZ and Al-Badr FB:
Inflammation as a contributing factor among postmenopausal Saudi
women with osteoporosis. Medicine (Baltimore). 96:e57802017.
View Article : Google Scholar
|
|
4
|
Paschalis EP, Gamsjaeger S, Hassler N,
Fahrleitner-Pammer A, Dobnig H, Stepan JJ, Pavo I, Eriksen EF and
Klaushofer K: Vitamin D and calcium supplementation for three years
in postmenopausal osteoporosis significantly alters bone mineral
and organic matrix quality. Bone. 95:41–46. 2017. View Article : Google Scholar
|
|
5
|
Gielen E, Bergmann P, Bruyère O, Cavalier
E, Delanaye P, Goemaere S, Kaufman JM, Locquet M, Reginster JY,
Rozenberg S, et al: Osteoporosis in frail patients: A consensus
paper of the belgian bone club. Calcif Tissue Int. 101:111–131.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ensrud KE and Crandall CJ: Osteoporosis
Ann Intern Med. 167:ITC17–ITC32. 2017. View Article : Google Scholar
|
|
7
|
Office of the Surgeon General (US): Bone
Health and Osteoporosis: A Report of the Surgeon General. Office of
the Surgeon General; Rockville, MD: 2004
|
|
8
|
Peng C, Li Z and Hu Y: Prevalence of
osteoporosis in China: A meta-analysis and systematic review. Bmc
Public Health. 16:10392016. View Article : Google Scholar
|
|
9
|
Zhou Y, Guan X, Chen X, Yu M, Wang C, Chen
X, Shi J, Liu T and Wang H: Angiotensin II/Angiotensin II receptor
blockade affects osteoporosis via the AT1/AT2-mediated
cAMP-dependent PKA pathway. Cells Tissues Organs. 204:25–37. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xu L, Zhang L, Zhang H, Yang Z, Qi L, Wang
Y and Ren S: The participation of fibroblast growth factor 23
(FGF23) in the progression of osteoporosis via JAK/STAT pathway. J
Cell Biochem. 119:3819–3828. 2018. View Article : Google Scholar
|
|
11
|
Wang Y, van Assen AHG, Reis CR,
Setroikromo R, van Merkerk R, Boersma YL, Cool RH and Quax WJ:
Novel RANKL DE-loop mutants antagonize RANK-mediated
osteoclastogenesis. FEBS J. 284:2501–2512. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Okabe I, Kikuchi T, Mogi M, Takeda H, Aino
M, Kamiya Y, Fujimura T, Goto H, Okada K, Hasegawa Y, et al: IL-15
and RANKL play a synergistically important role in
osteoclastogenesis. J Cell Biochem. 118:739–747. 2017. View Article : Google Scholar
|
|
13
|
Yang X, Gao W, Wang B, Wang X, Guo H, Xiao
Y, Kong L and Hao D: Picroside II Inhibits RANKL-mediated
Osteoclastogenesis by attenuating the NF-κB and MAPKs signaling
pathway in vitro and prevents bone loss in lipopolysaccharide
treatment mice. J Cell Biochem. 118:4479–4486. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ueno M, Cho K, Isaka S, Nishiguchi T,
Yamaguchi K, Kim D and Oda T: Inhibitory effect of sulphated
polysaccharide porphyran (isolated from Porphyra yezoensis) on
RANKL-induced differentiation of RAW264.7 cells into osteoclasts.
Phytother Res. 32:452–458. 2018. View
Article : Google Scholar
|
|
15
|
Chen X, Zhi X, Pan P, Cui J, Cao L, Weng
W, Zhou Q, Wang L, Zhai X, Zhao Q, et al: Matrine prevents bone
loss in ovariectomized mice by inhibiting RANKL-induced
osteoclastogenesis. FASEB J. 31:4855–4865. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dong J, Ding H, Liu Y, Yang Q, Xu N, Yang
Y and Ai X: Magnolol protects channel catfish from Aeromonas
hydrophila infection via inhibiting the expression of aerolysin.
Vet Microbiol. 211:119–123. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang Li M, Wang F, Wu X, Zhang X, Zhang
B, Wu N, Wang W, Weng Z, Liu HS, et al: Magnolol inhibits growth of
gallbladder cancer cells through the p53 pathway. Cancer Sci.
106:1341–1350. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wei W, Dejie L, Xiaojing S, Tiancheng W,
Yongguo C, Zhengtao Y and Naisheng Z: Magnolol inhibits the
inflammatory response in mouse mammary epithelial cells and a mouse
mastitis model. FEBS J. 38:16–26. 2015.
|
|
19
|
Yang B, Xu Y, Yu S, Huang Y, Lin L and
Liang X: Anti-angiogenic and anti-inflammatory effect of Magnolol
in the oxygen-induced retinopathy model. Inflamm Res. 65:81–93.
2016. View Article : Google Scholar
|
|
20
|
Park KR, Kim JY, Kim EC, Yun HM and Hong
JT: RANKL-induced osteoclastogenesis is suppressed by
4-O-methylhonokiol in bone marrow-derived macrophages. Arch Pharm
Res. 40:933–942. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jeong JH, Jin ES, Kim JY, Lee B, Min J,
Jeon SR, Lee M and Choi KH: The effect of biocomposite screws on
bone regeneration in a rat osteoporosis model. World Neurosurg.
106:964–972. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen P, Li Z and Hu Y: Prevalence of
osteoporosis in China: A meta-analysis and systematic review. Bmc
Public Health. 16:10392016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
McClung M, Baron R and Bouxsein M: An
update on osteoporosis pathogenesis, diagnosis, and treatment.
Bone. 98:372017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen X, Wang Z, Duan N, Zhu G, Schwarz EM
and Xie C: Osteoblast-osteoclast interactions. Connect Tissue Res.
59:99–107. 2018. View Article : Google Scholar
|
|
25
|
Stoecker WV, Carson A, Nguyen VH, Willis
AB, Cole JG and Rader RK: Addressing the crisis in the treatment of
osteoporosis: Better paths forward. J Bone Miner Res. 32:1386–1387.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu Q, Wang T, Zhou L, Song F, Qin A, Feng
HT, Lin XX, Lin Z, Yuan JB, Tickner J, et al: Nitidine chloride
prevents OVX-induced bone loss via suppressing NFATc1-mediated
osteoclast differentiation. Sci Rep. 6:366622016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kwak EJ, Lee YS and Choi EM: Effect of
magnolol on the function of osteoblastic MC3T3-E1 cells. Mediators
Inflamm. 2012.829650:2012.
|
|
28
|
Park JW, Yoon HJ, Kang WY, Cho S, Seong
SJ, Lee HW, Yoon YR and Kim HJ: G protein-coupled receptor 84
controls osteoclastogenesis through inhibition of NF-κB and MAPK
signaling pathways. J Cell Physiol. 233:1481–1489. 2018. View Article : Google Scholar
|
|
29
|
Chen X, Zhi X, Cao L, Weng W, Pan P, Hu H,
Liu C, Zhao Q, Zhou Q, Cui J and Su J: Matrine derivate MASM
uncovers a novel function for ribosomal protein S5 in
osteoclastogenesis and postmenopausal osteoporosis. Cell Death Dis.
8:e30372017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Guan H, Zhao L, Cao H, Chen A and Xiao J:
Epoxyeicosanoids suppress osteoclastogenesis and prevent
ovariectomy-induced bone loss. FASEB J. 29:1092–1101. 2015.
View Article : Google Scholar
|
|
31
|
Lu SH, Huang RY and Chou TC: Magnolol
ameliorates ligature-induced periodontitis in rats and
osteoclastogenesis: In vivo and in vitro study. Evid Based
Complement Alternat Med. 2013.634095:2013.
|
|
32
|
Kanzaki H, Shinohara F, Itohiya K,
Yamaguchi Y, Katsumata Y, Matsuzawa M, Fukaya S, Miyamoto Y, Wada S
and Nakamura Y: RANKL induces Bach1 nuclear import and attenuates
Nrf2-mediated antioxidant enzymes, thereby augmenting intracellular
reactive oxygen species signaling and osteoclastogenesis in mice.
FASEB J. 31:781–792. 2017. View Article : Google Scholar
|
